RU2015104097A - Соединения мочевины и их применение в качестве ингибиторов ферментов - Google Patents

Соединения мочевины и их применение в качестве ингибиторов ферментов Download PDF

Info

Publication number
RU2015104097A
RU2015104097A RU2015104097A RU2015104097A RU2015104097A RU 2015104097 A RU2015104097 A RU 2015104097A RU 2015104097 A RU2015104097 A RU 2015104097A RU 2015104097 A RU2015104097 A RU 2015104097A RU 2015104097 A RU2015104097 A RU 2015104097A
Authority
RU
Russia
Prior art keywords
compound
disease
composition
condition
symptoms
Prior art date
Application number
RU2015104097A
Other languages
English (en)
Other versions
RU2685425C2 (ru
Inventor
Карла Патрисиа да Кошта Перейра РОЗА
ДЕ НОРОНЬЯ Рита ГУЖМАН
Ласло Эрно КИСС
ДА СИЛЬВА Патрисиу Мануэль Виейра Араужу СУАРИШ
Доменику РУССУ
Жоржи Бруно Рейш ВАНОН
Уильям МАТОН
Original Assignee
Биал-Портела Энд Ка, С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Биал-Портела Энд Ка, С.А. filed Critical Биал-Портела Энд Ка, С.А.
Publication of RU2015104097A publication Critical patent/RU2015104097A/ru
Application granted granted Critical
Publication of RU2685425C2 publication Critical patent/RU2685425C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/24—Preparation of compounds containing amino groups bound to a carbon skeleton by reductive alkylation of ammonia, amines or compounds having groups reducible to amino groups, with carbonyl compounds
    • C07C209/26—Preparation of compounds containing amino groups bound to a carbon skeleton by reductive alkylation of ammonia, amines or compounds having groups reducible to amino groups, with carbonyl compounds by reduction with hydrogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/04—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups from amines with formation of carbamate groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)

Abstract

1. Соединение, имеющее следующую структуру:или его фармацевтически приемлемая соль, или производное.2. Фармацевтическая композиция, содержащая соединение по п. 1, вместе с одним или более фармацевтически приемлемыми вспомогательными веществами.3. Фармацевтическая композиция по п. 2, дополнительно содержащая один или более дополнительных активных фармацевтических ингредиентов, таких как анандамид, олеоилэтаноламид или пальмитоилэтаноламид.4. Соединение по п. 1, или композиция по п. 2, или 3 для применения в терапии.5. Соединение по п. 1, или композиция по п. 2, или 3 для применения в лечении или предупреждении состояния, развитие или симптомы которого связаны с субстратом фермента FAAH.6. Способ лечения или предупреждения состояния, развитие или симптомы которого связаны с субстратом фермента FAAH, включающий введение пациенту, нуждающемуся в таком лечении или предупреждении, терапевтически эффективного количества соединения по п. 1 или композиции по п. 2 или 3.7. Соединение для применения по п. 5 или способ по п. 6, отличающиеся тем, что указанное состояние представляет собой заболевание, связанное с эндоканнабиноидной системой.8. Соединение или способ по п. 7, отличающиеся тем, что заболевание выбрано из контроля аппетита, ожирения, метаболических нарушений, кахексии, анорексии, боли, воспаления, нейротоксичности, травмы нервной системы, инсульта, множественного склероза, повреждения спинного мозга, болезни Паркинсона, дискинезии, вызванной леводопой, болезни Хантингтона, синдрома Туретта, поздней дискинезии, дистонии, бокового амиотрофического склероза, болезни Альцгеймера, эпилепсии, шизофрении, тревожного расстройства, депрессии, бессонницы, тошноты, рвоты,

Claims (11)

1. Соединение, имеющее следующую структуру:
Figure 00000001
или его фармацевтически приемлемая соль, или производное.
2. Фармацевтическая композиция, содержащая соединение по п. 1, вместе с одним или более фармацевтически приемлемыми вспомогательными веществами.
3. Фармацевтическая композиция по п. 2, дополнительно содержащая один или более дополнительных активных фармацевтических ингредиентов, таких как анандамид, олеоилэтаноламид или пальмитоилэтаноламид.
4. Соединение по п. 1, или композиция по п. 2, или 3 для применения в терапии.
5. Соединение по п. 1, или композиция по п. 2, или 3 для применения в лечении или предупреждении состояния, развитие или симптомы которого связаны с субстратом фермента FAAH.
6. Способ лечения или предупреждения состояния, развитие или симптомы которого связаны с субстратом фермента FAAH, включающий введение пациенту, нуждающемуся в таком лечении или предупреждении, терапевтически эффективного количества соединения по п. 1 или композиции по п. 2 или 3.
7. Соединение для применения по п. 5 или способ по п. 6, отличающиеся тем, что указанное состояние представляет собой заболевание, связанное с эндоканнабиноидной системой.
8. Соединение или способ по п. 7, отличающиеся тем, что заболевание выбрано из контроля аппетита, ожирения, метаболических нарушений, кахексии, анорексии, боли, воспаления, нейротоксичности, травмы нервной системы, инсульта, множественного склероза, повреждения спинного мозга, болезни Паркинсона, дискинезии, вызванной леводопой, болезни Хантингтона, синдрома Туретта, поздней дискинезии, дистонии, бокового амиотрофического склероза, болезни Альцгеймера, эпилепсии, шизофрении, тревожного расстройства, депрессии, бессонницы, тошноты, рвоты, алкогольных психозов, привыканий к чрезмерному употреблению опиата, никотина, кокаина, алкоголя и психостимуляторов, гипертензии, злокачественной гипертензии, реперфузионного повреждения миокарда, атеросклероза, астмы, глаукомы, ретинопатии, рака, воспалительных заболеваний кишечника, острой и хронической печеночной недостаточности, такой как гепатит и цирроз печени, артрита и остеопороза.
9. Способ получения кислой соли N-метилциклопентиламина, включающий реакцию циклопентиламина с хлорформиатом или ди-трет-бутил карбонатом, с образованием циклопентилкарбамата, с последующим восстановлением циклопентилкарбамата и окислением до кислой соли N-метилциклопентиламина.
10. Способ получения кислой соли N-метилциклопентиламина, включающий восстановительное аминирование циклопентанона в присутствии кислой соли метиламина.
11. Способ получения соединения по п. 1, который включает способ по п. 9 или 10.
RU2015104097A 2012-07-24 2013-07-24 Соединения мочевины и их применение в качестве ингибиторов ферментов RU2685425C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261674970P 2012-07-24 2012-07-24
US61/674,970 2012-07-24
PCT/PT2013/000048 WO2014017936A2 (en) 2012-07-24 2013-07-24 Urea compounds and their use as enzyme inhibitors

Publications (2)

Publication Number Publication Date
RU2015104097A true RU2015104097A (ru) 2016-09-20
RU2685425C2 RU2685425C2 (ru) 2019-04-18

Family

ID=48986199

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015104097A RU2685425C2 (ru) 2012-07-24 2013-07-24 Соединения мочевины и их применение в качестве ингибиторов ферментов

Country Status (33)

Country Link
US (3) US9549915B2 (ru)
EP (1) EP2890684B1 (ru)
JP (1) JP6317345B2 (ru)
KR (1) KR102137714B1 (ru)
CN (1) CN104487422B (ru)
AR (1) AR091888A1 (ru)
AU (1) AU2013293650B2 (ru)
BR (1) BR112015001546B1 (ru)
CA (1) CA2879726A1 (ru)
CL (1) CL2015000178A1 (ru)
CY (1) CY1120148T1 (ru)
DK (1) DK2890684T3 (ru)
ES (1) ES2667056T3 (ru)
HK (1) HK1211920A1 (ru)
HR (1) HRP20180543T1 (ru)
HU (1) HUE037085T2 (ru)
IL (1) IL236630B (ru)
IN (1) IN2015DN00688A (ru)
LT (1) LT2890684T (ru)
ME (1) ME03018B (ru)
MX (1) MX365772B (ru)
NO (1) NO2923395T3 (ru)
NZ (1) NZ704651A (ru)
PH (1) PH12015500156B1 (ru)
PL (1) PL2890684T3 (ru)
PT (1) PT2890684T (ru)
RS (1) RS57146B1 (ru)
RU (1) RU2685425C2 (ru)
SG (1) SG11201500498SA (ru)
SI (1) SI2890684T1 (ru)
TW (1) TWI624460B (ru)
UA (1) UA116542C2 (ru)
WO (1) WO2014017936A2 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2667056T3 (es) * 2012-07-24 2018-05-09 Bial-Portela & Ca, S.A. Compuestos de urea y su uso como inhibidores enzimáticos
US9047327B2 (en) 2012-12-03 2015-06-02 Google Technology Holdings LLC Method and apparatus for developing a social hierarchy
EP3024825B1 (en) 2013-07-24 2017-06-21 BIAL - PORTELA & Cª, S.A. Imidazolecarboxamides and their use as faah inhibitors
GB201401198D0 (en) * 2014-01-24 2014-03-12 Bial Portela & Ca Sa Process for the syntheis of substituted urea compounds
US10702487B2 (en) 2017-08-19 2020-07-07 Frimline Private Limited Pharmaceutical composition for prevention of diet induced obesity
MY186286A (en) 2017-09-05 2021-07-05 Frimline Private Ltd A pharmaceutical composition for improving or preventing progression of chronic kidney disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2458965C3 (de) 1974-12-13 1979-10-11 Bayer Ag, 5090 Leverkusen 3-Amino-indazol-N-carbonsäure-Derivate, Verfahren zu ihrer Herstellung sowie sie enthaltende Arzneimittel
EP0014810A3 (en) 1979-01-18 1980-11-26 Fbc Limited Pesticidal pyrazoles, their production, compositions and uses, as well as intermediates and their preparation
JPH01203366A (ja) 1988-02-10 1989-08-16 Mitsui Petrochem Ind Ltd Ｎ−置換イミダゾール誘導体
WO1994010158A1 (en) 1992-10-28 1994-05-11 Toyama Chemical Co., Ltd. Novel 1,2-benzisoxazole derivative or salt thereof, and brain protective agent comprising the same
RU2157368C2 (ru) * 1994-09-26 2000-10-10 Сионоги Энд Ко., Лтд. Производные имидазола и фармацевтическая композиция на их основе
DE102004005172A1 (de) 2004-02-02 2005-08-18 Aventis Pharma Deutschland Gmbh Indazolderivate als Inhibitoren der Hormon Sensitiven Lipase
MX2007010076A (es) * 2005-02-17 2007-10-16 Astellas Pharma Inc Derivado de heterociclico-1-carboxilato que contiene nitrogeno no aromatico de piridilo.
FI20075264A0 (fi) * 2007-04-18 2007-04-18 Kuopion Yliopisto Heterosykliset fenyylikarbamaatit uusina FAAH-inhibiittoreina
WO2009126624A1 (en) * 2008-04-11 2009-10-15 Bristol-Myers Squibb Company Triazolo compounds useful as dgat1 inhibitors
BR122013027950A2 (pt) * 2008-12-24 2019-12-10 BIAL PORTELA & Cª S A compostos farmacêuticos
WO2012015324A1 (en) * 2010-07-29 2012-02-02 Bial - Portela & Ca, S.A. Process for the synthesis of substituted urea compounds
FR2965262A1 (fr) * 2010-09-24 2012-03-30 Sanofi Aventis Derives de nicotinamide, leur preparation et leur application en therapeutique
ES2667056T3 (es) * 2012-07-24 2018-05-09 Bial-Portela & Ca, S.A. Compuestos de urea y su uso como inhibidores enzimáticos

Also Published As

Publication number Publication date
EP2890684A2 (en) 2015-07-08
US9549915B2 (en) 2017-01-24
US20150174103A1 (en) 2015-06-25
PT2890684T (pt) 2018-05-07
CN104487422B (zh) 2017-07-25
BR112015001546A2 (pt) 2017-07-04
US10023541B2 (en) 2018-07-17
NO2923395T3 (ru) 2018-01-27
PL2890684T3 (pl) 2018-08-31
RU2685425C2 (ru) 2019-04-18
IL236630A0 (en) 2015-02-26
NZ704651A (en) 2017-09-29
TW201408650A (zh) 2014-03-01
EP2890684B1 (en) 2018-02-14
DK2890684T3 (en) 2018-05-07
KR20150038182A (ko) 2015-04-08
US20170101381A1 (en) 2017-04-13
AR091888A1 (es) 2015-03-11
RS57146B1 (sr) 2018-07-31
WO2014017936A3 (en) 2014-09-18
LT2890684T (lt) 2018-05-10
PH12015500156A1 (en) 2015-03-16
SG11201500498SA (en) 2015-03-30
AU2013293650A1 (en) 2015-02-19
ME03018B (me) 2018-10-20
AU2013293650B2 (en) 2017-05-25
HUE037085T2 (hu) 2018-08-28
JP2015522657A (ja) 2015-08-06
HK1211920A1 (en) 2016-06-03
CL2015000178A1 (es) 2015-06-19
MX2015000968A (es) 2015-04-10
UA116542C2 (uk) 2018-04-10
TWI624460B (zh) 2018-05-21
IN2015DN00688A (ru) 2015-06-26
SI2890684T1 (en) 2018-06-29
IL236630B (en) 2018-04-30
KR102137714B1 (ko) 2020-07-27
US11046654B2 (en) 2021-06-29
CA2879726A1 (en) 2014-01-30
WO2014017936A2 (en) 2014-01-30
HRP20180543T1 (hr) 2018-06-29
CY1120148T1 (el) 2018-12-12
JP6317345B2 (ja) 2018-04-25
ES2667056T3 (es) 2018-05-09
PH12015500156B1 (en) 2015-03-16
MX365772B (es) 2019-06-13
CN104487422A (zh) 2015-04-01
BR112015001546B1 (pt) 2021-02-23
US20190135764A1 (en) 2019-05-09

Similar Documents

Publication Publication Date Title
RU2015104097A (ru) Соединения мочевины и их применение в качестве ингибиторов ферментов
IL188172A0 (en) Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use
DK1933833T3 (da) Terapi til behandling af overaktiv blære
NZ619076A (en) Isoxazolines as inhibitors of fatty acid amide hydrolase
EA201170018A1 (ru) Разагилин для изменения течения болезни паркинсона
EA016687B8 (ru) Производные циклопропиламида
RU2009145541A (ru) Терапевтические соединения
CA2656875A1 (en) Substituted n-bicyclicalkyl bicyclic carboxyamide compounds
NZ596656A (en) New compositions for treating cmt and related disorders
EA201171088A1 (ru) Лечение дискинезии при различных расстройствах
JP2012520321A5 (ru)
EA200901237A1 (ru) Применение димирацетама при лечении хронической боли
HK1141019A1 (en) Carbamoyloxy arylalkanoyl arylpiperazine compound, pharmaceutical compositions comprising the compound and method for treating pain, anxiety and depression by administering the compound
EA201171087A1 (ru) СПОСОБЫ ВВЕДЕНИЯ (4aR,10aR)-1-н-ПРОПИЛ-1,2,3,4,4a,5,10,10a-ОКТАГИДРОБЕНЗО[g]ХИНОЛИН-6,7-ДИОЛА И РОДСТВЕННЫХ СОЕДИНЕНИЙ ЧЕРЕЗ СЛИЗИСТУЮ ОБОЛОЧКУ ПОЛОСТИ РТА, СЛИЗИСТУЮ ОБОЛОЧКУ НОСА ИЛИ КОЖУ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ
WO2006079077A3 (en) Use of diltiazem or analogs thereof as modulators of ghrelin receptor
EP2772481A8 (en) Novel compound as kcnq potassium channel agonist, preparation method therefor and use thereof
RU2016104221A (ru) Имидазолкарбоксамиды и их применение в качестве ингибиторов гидролазы амидов жирных кислот
JP2016525543A5 (ru)
WO2006133231A3 (en) Treatment for neurodegenerative diseases
CA2663408A1 (en) Substituted pyridylmethyl bicyclocarboxyamide compounds
RU2009110245A (ru) Лечение фиброзирующих нарушений
EA201000116A1 (ru) Интраназальные фармацевтические композиции, содержащие янтарную кислоту
NZ622480A (en) Meta-substituted biphenyl peripherally restricted faah inhibitors
EA200800125A1 (ru) Фармацевтическая композиция, включающая 1-(3-хлорфенил)-3-алкилпиперазин, для лечения расстройств аппетита